Head-to-head evidence
Ivonescimab vs JS207
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 + VEGFA · full Non-Small Cell Lung Cancer pipeline
Ivonescimab
Marketed by Akeso and partners
NCT04900363 · Phase 1/2 · completed
The study assigned all participants to ivonescimab without randomization, blinding, or a comparison arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07086326 (registry estimate)
JS207
Developed by Shanghai Junshi Bioscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT06944470 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivonescimab's landscape · JS207's landscape